You are being asked to participate in this research study because you have been diagnosed with a type of non-muscle invasive bladder cancer (NMIBC) and when you were previously treated with Bacillus Calmette-Guerin (BCG), a standard therapy for NMIBC, you had a limited or no response to the treatment (BCG unresponsive). This means that your disease either did not improve on treatment or progressed following at least one course of treatment with BCG, or it returned within 12 months after receiving at least two courses of BCG treatment. The current standard of care for BCG unresponsive bladder cancer is for the surgeon to offer removal of your bladder (cystectomy), which may reduce the risk of your disease progressing to invasion of the muscle layer of your bladder but may be associated with complications, morbidity and decreased quality of life.

Researchers are trying to find out if they can slow the growth of prostate cancer by adding green tea to patients treatment. Researchers are also trying to find out if this could be better or worse than usual care patients get.

Patients with previous negative prostate biopsy, but still considered at risk for prostate cancer may be eligible to take part in a study where they will have have further tests performed along with their scheduled repeat prostate biopsy. These research performed tests are being evaluated in hopes of making more accurate diagnosis and reduce the need for repeat biopsies.

o assess the perception of harm of electronic nicotine delivery systems, such as the e-cigarette, from bladder cancer patients.

The purpose of this study is to culturally and linguistically adapt a decision aid website for Lantinx populations. This decision aid website was created to assist parents and providers in making a shared decision about surgery to repair hypospadias.

Develop a device to measure patient preferences in the treatment of bladder cancer.

To better understand and address kidney stone-forming patients' sexual concerns

This project is a randomized clinical trial (study that randomly assigns participants to one arm to fairly understand outcomes) that aims to assess if information from gene expression classifier (GEC) testing is helpful for both patients and their doctors in the management of care for newly diagnosed prostate cancer patients.

This study will evaluate the safety and tolerability of EG 70, a gene therapy, which is given inside the bladder, and its effectiveness on eliminating bladder tumors in patients with NMIBC who have failed BCG therapy and have been recommended to have their bladder removed. Giving the study drug inside the bladder is to expose cells in the lining of the bladder, including your cancerous cells, to genes that may cause an immune response inside the bladder and kill the tumor cells.

The rationale for this study is to determine if there is a difference in symptoms or complications among patients undergoing uncomplicated ureteroscopy for stone removal with shorter indwelling stent duration. Curently there are only a few small studies exploring the optimal duration of stent placement after stent placement and no multicenter randomized control trials.